MIG Capital

MIG Capital MIG Capital is Germany's only retail-funded VC, with €1.2B+ committed across 17 BaFin-regulated funds. The dual focus is life science and deep tech. biopharmaceuticals, energy, advanced computing, and medtech. The portfolio of 30 active companies (50+ historical) has received €730M+ in total investment, with €43M deployed in 2023. The exit track record includes a defining bet: BioNTech, which went on to develop one of the COVID vaccines. Other notable outcomes include Immatics and C